EAM
Exome Asset Management Portfolio holdings
AUM
$110M
This Quarter Return
+9.77%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$133M
AUM Growth
+$133M
(-10%)
Cap. Flow
-$15.9M
Cap. Flow
% of AUM
-11.94%
Top 10 Holdings %
Top 10 Hldgs %
37.04%
Holding
83
New
23
Increased
12
Reduced
17
Closed
24
Top Buys
| 1 |
Humana
HUM
|
$4.58M |
| 2 |
Syndax Pharmaceuticals
SNDX
|
$4.22M |
| 3 |
Arvinas
ARVN
|
$4.19M |
| 4 |
Boston Scientific
BSX
|
$3.62M |
| 5 |
Soleno Therapeutics
SLNO
|
$3.47M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$6.55M |
| 2 |
TG Therapeutics
TGTX
|
$4.86M |
| 3 |
Align Technology
ALGN
|
$4.76M |
| 4 |
Cigna
CI
|
$4.23M |
| 5 |
BioNTech
BNTX
|
$4.1M |
Sector Composition
| 1 | Healthcare | 98.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Nektar Therapeutics
NKTR
$543M
| $575K | 0.43% |
+618,174
| New | +$575K |
|
52
Aprea Therapeutics
APRE
$8.91M
| $420K | 0.32% |
127,960
-9,214
| -7% | -$30.2K |
|
53
Akebia Therapeutics
AKBA
$827M
| $391K | 0.29% |
+205,956
| New | +$391K |
|
54
Madrigal Pharmaceuticals
MDGL
$9.7B
| $305K | 0.23% |
+987
| New | +$305K |
|
55
Leap Therapeutics
LPTX
$12M
| $295K | 0.22% |
102,631
| – | – |
|
56
Mersana Therapeutics
MRSN
$34.8M
| $250K | 0.19% |
172,924
-1,005,646
| -85% | -$1.45M |
|
57
Arbutus Biopharma
ABUS
$753M
| $92.5K | 0.07% |
+28,300
| New | +$92.5K |
|
58
Kura Oncology
KURA
$732M
| – | – |
-90,305
| Closed | -$1.76M |
|
59
Insmed
INSM
$30.3B
| – | – |
-33,600
| Closed | -$2.45M |
|
60
Glaukos
GKOS
$5.42B
| – | – |
-25,857
| Closed | -$3.37M |
|
|
61
Cigna
CI
$80.2B
| – | – |
-12,200
| Closed | -$4.23M |
|
|
62
BioNTech
BNTX
$24.1B
| – | – |
-34,552
| Closed | -$4.1M |
|
63
Biogen
BIIB
$20.8B
| – | – |
-13,317
| Closed | -$2.57M |
|
64
BioCryst Pharmaceuticals
BCRX
$1.74B
| – | – |
-196,500
| Closed | -$1.49M |
|
|
65
Ascendis Pharma
ASND
$12.1B
| – | – |
-43,849
| Closed | -$6.55M |
|
66
Amgen
AMGN
$153B
| – | – |
-6,700
| Closed | -$2.16M |
|
|
67
Align Technology
ALGN
$9.59B
| – | – |
-18,700
| Closed | -$4.76M |
|
68
Agios Pharmaceuticals
AGIO
$2.36B
| – | – |
-66,200
| Closed | -$2.94M |
|
|
ADAG
69
Adagene
ADAG
$103M
| – | – |
-262,625
| Closed | -$583K |
|
70
Acrivon Therapeutics
ACRV
$42.2M
| – | – |
-116,757
| Closed | -$817K |
|
|
PROC
71
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
| – | – |
-126,901
| Closed | -$280K |
|
|
RVNC
72
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-347,600
| Closed | -$1.8M |
|
|
SYRS
73
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-298,575
| Closed | -$642K |
|
74
Viridian Therapeutics
VRDN
$1.59B
| – | – |
-174,400
| Closed | -$3.97M |
|
|
75
TG Therapeutics
TGTX
$5.03B
| – | – |
-207,627
| Closed | -$4.86M |
|